The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells.
Juvenescence will support the venture with $10m in equity financing and drug development expertise.
Led by Kelsey Moody, CEO, and Aaron Wolfe, COO, Antoxerene is a small molecule drug discovery platform. Founded in 2016, the company has largely focused on small molecule discovery through the study of protein-protein interactions that drive the survival of toxic senescent cells, which have been implicated in the onset and progression of several age-associated diseases.
The company works to identify and develop novel compounds to selectively destroy these cells and restore tissue function.
It is a portfolio company of Ichor Therapeutics.